Known targets — ChEMBL curated mechanism
ADRB1ADRB2ATP4AATP4BAXLCHRM2CHRM3DRD2FLT3HRH1HTR2AHTR2BHTR2CKCNH2KMT2AMAP2K1MAP2K2MEN1MLNRPLK4RENS1PR1SLC6A2SLC6A4atpAatpBatpCatpDatpEatpFatpFHatpGpol
The experimentally established mechanism targets of Fumaric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 known ✓ | O00255 | 1/20 | 0.93 |
| ▸ | KMT2A known ✓ | Q03164 | 1/20 | 0.93 |
| ▸ | LSS | P48449 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fumaric Acid SCHEMBL4437311 | 1.00 | LSS (1.00) | LSSMEN1KMT2A | |
| Fumaric Acid SCHEMBL29455114 | 1.00 | LSS (1.00) | LSSMEN1KMT2A | |
| SCHEMBL3674881 | 0.96 | LSS (1.00) | LSSMEN1KMT2A | |
| Bromide SCHEMBL7685880 | 0.95 | LSS (0.98) | LSSMEN1KMT2A | |
| Fumaric Acid SCHEMBL12477423 | 0.94 | LSS (0.90) | LSSMEN1KMT2A | |
| SCHEMBL8760830 | 0.91 | LSS (0.89) | LSSMEN1KMT2A | |
| Fumaric Acid SCHEMBL7681307 | 0.90 | LSS (1.00) | LSSMEN1KMT2A | |
| Fumaric Acid SCHEMBL7681297 | 0.90 | LSS (1.00) | LSSMEN1KMT2A | |
| Fumaric Acid SCHEMBL7685917 | 0.89 | LSS (0.82) | LSSMEN1KMT2A | |
| Fumaric Acid SCHEMBL7685922 | 0.89 | LSS (0.82) | LSSMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10143686-B2 | Oxidosqualene cyclase as a protein target for anticancer therapeutics | THE CURATORS OF THE UNIVERSITY OF MISSOURI (US) | 2018-12-04 | — | — | US | claimed |
| US-20140005187-A1 | OXIDOSQUALENE CYCLASE AS A PROTEIN TARGET FOR ANTICANCER THERAPEUTICS | THE CURATORS OF THE UNIVERSITY OF MISSOURI (US) | 2014-01-02 | — | — | US | claimed |
| EP-2658544-A2 | OXIDOSQUALENE CYCLASE AS A PROTEIN TARGET FOR ANTICANCER THERAPEUTICS | The Curators Of The University Of Missouri (US) | 2013-11-06 | — | — | EP | claimed |
| WO-2012092114-A2 | OXIDOSQUALENE CYCLASE AS A PROTEIN TARGET FOR ANTICANCER THERAPEUTICS | THE CURATORS OF THE UNIVERSITY OF MISSOURI (US) | 2012-07-05 | — | — | WO | claimed |
| EP-2866810-B9 | INDUCTION OF ESTROGEN RECEPTOR BETA BY CHOLESTEROL BIOSYNTHESIS INHIBITORS AND METHODS OF TREATMENT OF CANCER | UNIV MISSOURI (US) | 2019-06-26 | — | — | EP | disclosed |
| US-10143686-B2 | Oxidosqualene cyclase as a protein target for anticancer therapeutics | THE CURATORS OF THE UNIVERSITY OF MISSOURI (US) | 2018-12-04 | — | — | US | disclosed |
| EP-2866810-B1 | INDUCTION OF ESTROGEN RECEPTOR BETA BY CHOLESTEROL BIOSYNTHESIS INHIBITORS AND METHODS OF TREATMENT OF CANCER | UNIV MISSOURI (US) | 2018-10-03 | — | — | EP | disclosed |
| US-20150366824-A1 | INDUCTION OF ESTROGEN RECEPTOR BETA BY CHOLESTEROL BIOSYNTHESIS INHIBITORS AND METHODS OF TREATMENT OF CANCER | THE CURATORS OF THE UNIVERSITY OF MISSOURI | 2015-12-24 | — | — | US | disclosed |
| US-20140005187-A1 | OXIDOSQUALENE CYCLASE AS A PROTEIN TARGET FOR ANTICANCER THERAPEUTICS | THE CURATORS OF THE UNIVERSITY OF MISSOURI (US) | 2014-01-02 | — | — | US | disclosed |
| EP-2658544-A2 | OXIDOSQUALENE CYCLASE AS A PROTEIN TARGET FOR ANTICANCER THERAPEUTICS | The Curators Of The University Of Missouri (US) | 2013-11-06 | — | — | EP | disclosed |
| WO-2012092114-A2 | OXIDOSQUALENE CYCLASE AS A PROTEIN TARGET FOR ANTICANCER THERAPEUTICS | THE CURATORS OF THE UNIVERSITY OF MISSOURI (US) | 2012-07-05 | — | — | WO | disclosed |
| US-20100021893-A1 | Modulators of lanosterol synthetase for treating acne or hyperseborrhea | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2010-01-28 | — | — | US | disclosed |
| US-20090270506-A1 | CRYSTALLINE STRUCTURE OF OXIDOSQUALENE SYNTHASE | RUF ARMIN | 2009-10-29 | — | — | US | disclosed |
| EP-2046980-A2 | MODULATORS OF LANOSTEROL SYNTHETASE IN THE TREATMENT OF ACNE OR OF HYPERSEBORRHOEA | Galderma Research & Development (FR) | 2009-04-15 | — | — | EP | disclosed |
| WO-2008009852-A2 | MODULATORS OF LANOSTEROL SYNTHETASE IN THE TREATMENT OF ACNE OR OF HYPERSEBORRHOEA | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2008-01-24 | — | — | WO | disclosed |
| US-20050202548-A1 | Crystalline structure of oxidosqualene synthase | HOFFMANN-LA ROCHE INC. | 2005-09-15 | — | — | US | disclosed |
| EP-1498482-A2 | Crystal structure of oxidosqualene cyclase | F. HOFFMANN-LA ROCHE AG (CH) | 2005-01-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150366824-A1 | INDUCTION OF ESTROGEN RECEPTOR BETA BY CHOLESTEROL BIOSYNTHESIS INHIBITORS AND METHODS OF TREATMENT OF CANCER | ESRRA, ESRRB, ESRRG | MEN1 4535/4885KMT2A 3444/4885LSS 276/4885 |
| US-20140005187-A1 | OXIDOSQUALENE CYCLASE AS A PROTEIN TARGET FOR ANTICANCER THERAPEUTICS | HMGCR, DHCR7, CYP46A1 | MEN1 2703/4885KMT2A 3327/4885LSS 128/4885 |
| US-10143686-B2 | Oxidosqualene cyclase as a protein target for anticancer therapeutics | COASY, HCCS, OSBP | MEN1 3695/4885KMT2A 3831/4885LSS 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.